196 related articles for article (PubMed ID: 37350965)
1. Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies.
Shi T; Wang H; Wei J; Wang J; Fan Y; Zheng C; Che X
Front Immunol; 2023; 14():1230591. PubMed ID: 37350965
[No Abstract] [Full Text] [Related]
2. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.
Puccini A; Battaglin F; Iaia ML; Lenz HJ; Salem ME
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32393474
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Tumor microenvironment, immunotherapy, and drug resistance in breast and gastrointestinal cancer.
Deng X; Xie J; Yang L; Yang DH; Zheng S
Front Immunol; 2023; 14():1265704. PubMed ID: 37711625
[No Abstract] [Full Text] [Related]
4. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
Moehler M; Göpfert K; Lenz HJ
Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
[TBL] [Abstract][Full Text] [Related]
5. Exploring the landscape of drug resistance in gastrointestinal cancer immunotherapy: A review.
Yao N; Li W; Duan N; Xu G; Yu G; Qu J
Medicine (Baltimore); 2024 Jan; 103(2):e36957. PubMed ID: 38215151
[TBL] [Abstract][Full Text] [Related]
6. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.
Zhang Y; Xu J; Zhang N; Chen M; Wang H; Zhu D
Cancer Lett; 2019 Aug; 458():123-135. PubMed ID: 31121212
[TBL] [Abstract][Full Text] [Related]
7. Editorial: New immunotherapy strategies and related therapeutic targets for gastrointestinal malignancies.
Ramamoorthi G
Front Immunol; 2024; 15():1389781. PubMed ID: 38524142
[No Abstract] [Full Text] [Related]
8. Metabolic reprogramming, autophagy, and ferroptosis: Novel arsenals to overcome immunotherapy resistance in gastrointestinal cancer.
Wang X; Zhou L; Wang H; Chen W; Jiang L; Ming G; Wang J
Cancer Med; 2023 Nov; 12(21):20573-20589. PubMed ID: 37860928
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
10. Understanding relevant immune mechanisms in gastrointestinal oncology.
Cetin B; Gumusay O
J Oncol Pharm Pract; 2021 Jul; 27(5):1222-1234. PubMed ID: 33557689
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
[TBL] [Abstract][Full Text] [Related]
13. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
Abdul-Latif M; Townsend K; Dearman C; Shiu KK; Khan K
Cancer Treat Rev; 2020 Aug; 88():102030. PubMed ID: 32505807
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies.
Xiong J; Wang QQ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):430-439. PubMed ID: 35907687
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.
Long J; Lin J; Wang A; Wu L; Zheng Y; Yang X; Wan X; Xu H; Chen S; Zhao H
J Hematol Oncol; 2017 Aug; 10(1):146. PubMed ID: 28774337
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Sundar R; Huang KK; Kumar V; Ramnarayanan K; Demircioglu D; Her Z; Ong X; Bin Adam Isa ZF; Xing M; Tan AL; Tai DWM; Choo SP; Zhai W; Lim JQ; Das Thakur M; Molinero L; Cha E; Fasso M; Niger M; Pietrantonio F; Lee J; Jeyasekharan AD; Qamra A; Patnala R; Fabritius A; De Simone M; Yeong J; Ng CCY; Rha SY; Narita Y; Muro K; Guo YA; Skanderup AJ; So JBY; Yong WP; Chen Q; Göke J; Tan P
Gut; 2022 Jul; 71(7):1277-1288. PubMed ID: 34433583
[TBL] [Abstract][Full Text] [Related]
18. Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications.
Wang DK; Zuo Q; He QY; Li B
Front Immunol; 2021; 12():705999. PubMed ID: 34447376
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges.
Ding YN; Xue M; Tang QS; Wang LJ; Ding HY; Li H; Gao CC; Yu WP
World J Gastroenterol; 2022 Oct; 28(37):5403-5419. PubMed ID: 36312831
[TBL] [Abstract][Full Text] [Related]
20. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
Chmiel P; Gęca K; Michalski A; Kłosińska M; Kaczyńska A; Polkowski WP; Pelc Z; Skórzewska M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
